Drug Interaction Report

GENERALLY AVOID: The use of anifrolumab, a type 1 interferon (IFN) receptor antagonist antibody with other biologic therapies, including B-cell-targeted therapies may increase the risk of infections. Anifrolumab alone has been reported to increase the risk of infections, including serious and fatal infections. However, concomitant use of anifrolumab with these therapies has not been studied. In the randomized, double-blind, placebo-controlled, phase 3 study of anifrolumab in adult subjects with active Systemic Lupus Erythematosus (SLE) (n=365), if patients had received treatment with a biologic agent, or a B-cell-depleting agent (e.g., ocrelizumab, ofatumumab, obinutuzumab, rituximab), they were required to complete a wash-out period of at least 5 half-lives prior to enrolment in the study.

MANAGEMENT: Until further information is available, anifrolumab is not recommended for use in combination with biologics with immunosuppressant effects, including B-cell-targeted therapies such as ocrelizumab, ofatumumab, obinutuzumab, or rituximab.